Metastasis suppressor genes: Signal transduction, cross-talk and the potential for modulating the behavior of metastatic cells

Anti-Cancer Drugs

Volumn 15, Issue 6, 2004, Pages 559-568

  Berger, Jonathan C ^a   Vander Griend, Donald ^b   Stadler, Walter M ^b,c   Rinker Schaeffer, Carrie ^b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c University of Chicago   (United States)

Author keywords

Neoplasm; Neoplasm metastasis; Receptor cross talk; Signal transduction; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CD82 ANTIGEN; ESTRADIOL; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IMMUNOMODULATING AGENT; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN INHIBITOR; RAF PROTEIN; RETINOIC ACID; STEROID HORMONE; TRICHOSTATIN A;

BRMS 1 GENE; CANCER CELL; CANCER MODEL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COLON ADENOCARCINOMA; CRSP 3 GENE; DNA METHYLATION; DNA MICROARRAY; DRG 1 GENE; DRUG DESIGN; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE CONTROL; GENE FUNCTION; GENE IDENTIFICATION; GENE REPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; KAI 1 GENE; KISS 1 GENE; METASTASIS INHIBITION; MKK 4 GENE; NM 23 GENE; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHO GD 12 GENE; RKIP GENE; SIGNAL TRANSDUCTION; SSECKS GENE; SUPPRESSOR GENE; UPREGULATION; VDUP 1 GENE;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM METASTASIS; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION;

EID: 3142695383     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000132233.36512.fa     Document Type: Review

References (84)

1. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1989; 8:98-101.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics [Comment] [Erratum appears in CA Cancer J Clin 2002; 52:119]. CA Cancer J Clin 2002; 52:23-47.
3. MacDonald IC, Groom AC, Chambers AF. Cancer spread and micrometastasis development: quantitative approaches for in vivo models. BioEssays 2002; 24:885-893.
4. Feynman RP. Six Easy Pieces: Essentials of Physics, Explained by its Most Brilliant Teacher. Reading, MA: Helix Books; 1995, p. 145.
5. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347:1593-1603.
6. Hall SJ, Thompson TC. Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines. Clin Exp Metastasis 1997; 15:630-638.
7. Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM, Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999; 59:5483-5487.
8. Goldberg SF, Harms JF, Quon K, Welch DR. Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clin Exp Metastasis 1999; 17:601-607.
9. Raj GV, Moreno JG, Gomella LG. Utilization of polymerase chain reaction technology in the detection of solid tumors [Comment]. Cancer 1998; 82:1419-1442.
10. Cher ML, de Oliveira JG, Beaman AA, Nemeth JA, Hussain M, Wood Jr DP. Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate cancer. Clin Cancer Res 1999; 5:2421-2425.
11. Melchior SW, Corey E, Ellis WJ, Ross AA, Layton TJ, Oswin MM, et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997; 3:249-256.
12. Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC, et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 2000; 60:2541-2546.
13. Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site [Comment]. J Urol 2003; 169:1122-1133.
14. Shevde LA, Welch DR. Metastasis suppressor pathways - an evolving paradigm. Cancer Lett 2003; 198:1-20.
15. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80:200-204.
16. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2 [Comment]. Science 1995; 268:884-886.
17. Seraj MJ, Samant RS, Verderame MF, Welch DR. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 2000; 60:2764-2769.
18. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene [Comment] [Erratum appears in J Natl Cancer Inst 1997; 89:1549). J Natl Cancer Inst 1996; 88:1731-1737.
19. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002; 62:6418-6423.
20. Goldberg SF, Miele ME, Hatta N, Takata M, Paquette-Straub C, Freedman LP, et al. Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res 2003; 63:432-440.
21. Xia W, Unger P, Miller L, Nelson J, Gelman IH. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 2001; 61:5644-5651.
22. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, et al. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis [Comment]. J Natl Cancer Inst 2003; 95:878-889.
23. Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res 2000; 60:749-755.
24. Steeg PS, Ouatas T, Halverson D, Palmieri D, Salerno M. Metastasis suppressor genes: basic biology and potential clinical use. Clin Breast Cancer 2003; 4:51-62.
25. Bevilacqua G, Sobel ME, Liotta LA, Steeg PS. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res 1989; 49:5185-5190.
26. Salerno M, Ouatas T, Palmieri D, Steeg PS. Inhibition of signal transduction by the nm23 metastasis suppressor: possible mechanisms. Clin Exp Metastasis 2003; 20:3-10.
27. Roymans D, Willems R, Van Blockstaele DR, Slegers H. Nucleoside diphosphate kinase (NDPK/NM23) and the waltz with multiple partners: possible consequences in tumor metastasis. Clin Exp Metastasis 2002; 19:465-476.
28. Postel EH, Berberich SJ, Flint SJ, Ferrone CA. Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis [Comment]. Science 1993; 261:478-480.
29. Hartsough MT, Morrison DK, Salerno M, Palmieri D, Ouatas T, Mair M, et al. Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of Ras via a histidine protein kinase pathway. J Biol Chem 2002; 277:32389-32399.
30. Chekmareva MA, Hollowell CM, Smith RC, Davis EM, LeBeau MM, Rinker-Schaeffer CW. Localization of prostate cancer metastasis-suppressor activity on human chromosome 17. Prostate 1997; 33:271-280.
31. Sanchez I, Hughes RT, Mayer BJ, Yee K, Woodgett JR, Avruch J, et al. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 1994; 372:794-798.
32. Cuenda A. Mitogen-activated protein kinase kinase 4 (MKK4). Int J Biochem Cell Biol 2000; 32:581-587.
33. Yamada SD, Hickson JA, Hrobowski Y, Vander Griend DJ, Benson D, Montag A, et al. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res 2002; 62:6717-6723.
34. 2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells. Cancer Res 2000; 60:400-408.
35. Kim HL, Vander Griend DJ, Yang X, Benson DA, Dubauskas Z, Yoshida BA, et al. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res 2001; 61:2833-2837.
36. Su GH, Hilgers W, Shekher MC, Tang DJ, Yeo CJ, Hruban RH, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998; 58:2339-2342.
37. Wu CW, Li AF, Chi CW, Huang CL, Shen KH, Liu WY, et al. Human gastric cancer kinase profile and prognostic significance of MKK4 kinase. Am J Pathol 2000; 156:2007-2015.
38. Chae KS, Ryu BK, Lee MG, Byun DS, Chi SG. Expression and mutation analyses of MKK4, a candidate tumour suppressor gene encoded by chromosome 17p, in human gastric adenocarcinoma. Eur J Cancer 2002; 38:2048-2057.
39. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996; 56:4387-4390.
40. Ueda T, Ichikawa T, Tamaru J, Mikata A, Akakura K, Akimoto S, et al. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol 1996; 149:1435-1440.
41. Morris VL, Schmidt EE, Koop S, MacDonald IC, Grattan M, Khokha R, et al. Effects of the disintegrin eristostatin on individual steps of hematogenous metastasis. Exp Cell Res 1995; 219:571-578.
42. Herynk MH, Radinsky R. The coordinated functional expression of epidermal growth factor receptor and c-Met in colorectal carcinoma metastasis. In Vivo 2000; 14:587-596.
43. Stafford LJ, Xia C, Ma W, Cai Y, Liu M. Identification and characterization of mouse metastasis-suppressor KiSS1 and its G-protein-coupled receptor. Cancer Res 2002; 62:5399-5404.
44. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001; 411:613-617.
45. Shirasaki F, Takata M, Hatta N, Takehara K. Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3-q23. Cancer Res 2001; 61:7422-7425.
46. Habermann H, Ray V, Habermann W, Prins GS. Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer. J Urol 2002; 167:655-660.
47. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, et al. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 2003; 63:1731-1736.
48. Motwani M, Sirotnak FM, She Y, Commes T, Schwartz GK. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res 2002; 62:3950-3955.
49. Evers EE, Zondag GC, Malliri A, Price LS, ten Klooster JP, van der Kammen RA, et al. Rho family proteins in cell adhesion and cell migration. Eur J Cancer 2000; 36:1269-1274.
50. Jaffe AB, Hall A. Rho GTPases in transformation and metastasis. Adv Cancer Res 2002; 84:57-80.
51. Nauert JB, Klauck TM, Langeberg LK, Scott JD. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr Biol 1997; 7:52-62.
52. Nicolson G. Tumor Microenvironment: paracrine and autocrine growth mechanisms and metastasis to specific sites. Front Radiat Ther Oncol 1994; 28:11-24.
53. Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells [Comment]. J Natl Cancer Inst 1990; 82:1890-1898.
54. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81:807-869.
55. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22:153-183.
56. Morrison DK. KSR: a MAPK scaffold of the Ras pathway? J Cell Sci 2001; 114:1609-1612.
57. Lozano J, Xing R, Cai Z, Jenson HL, Trempus C, Mark W, et al. Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice. Cancer Res 2003; 63:4232-4238.
58. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM, et al. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 2000; 20:3079-3085.
59. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994; 369:156-160.
60. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63:1684-1695.
61. Kennedy NJ, Sluss HK, Jones SN, Bar-Sagi D, Flavell RA, Davis RJ. Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev 2003; 17:629-637.
62. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001; 12:863-879.
63. Cole WH, Roberts S, Watne A, McGrew E. The dissemination of cancer cells. Bull NY Acad Med 1958; 34:163-183.
64. Roberts SS, Watne AL, McGrath R, McGrew E, Nanos S, Cole WH. Cancer cells in the circulating blood. Surg Forum 1957; 8:146-151.
65. Roberts S, Watne A, McGrath R, McGrew E, Cole WH. Technique and results of isolation of cancer cells from the circulating blood. AMA Arch Surg 1958; 76:334-346.
66. Roberts SS, Watne AL, McGrath R, McGrew E, Cole WH. The response of cancer cells in the circulating blood to surgical stress and chemotherapy. Surg Forum 1958; 9:595-598.
67. Oefelein MG, Kaul K, Herz B, Blum MD, Holland JM, Keeler TC, et al. Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy [Comment]. J Urol 1996; 155:238-242.
68. Gao C-L, Rawal SK, Sun L, Ali A, Connelly RR, Banez LL, et al. Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. Clin Cancer Res 2003; 9:2545-2550.
69. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P11 Study [Comment]. J Natl Cancer Inst 1998; 90:1371-1388.
70. Natarajan K, Mori N, Artemov D, Bhujwalla ZM. Exposure of human breast cancer cells to the anti-inflammatory agent indomethacin alters choline phospholipid metabolites and Nm23 expression. Neoplasia 2002; 4:409-416.
71. Natarajan K, Mori N, Artemov D, Aboagye EO, Chacko VP, Bhujwalla ZM. Phospholipid profiles of invasive human breast cancer cells are altered towards a less invasive phospholipid profile by the anti-inflammatory agent indomethacin. Adv Enz Reg 2000; 40:271-284.
72. Yu HG, Huang JA, Yang YN, Huang H, Luo HS, Yu JP, et al. The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells [Comment]. Eur J Clin Invest 2002; 32:838-846.
73. Lin KH, Wang WJ, Wu YH, Cheng SY. Activation of antimetastatic Nm23-H1 gene expression by estrogen and its alpha-receptor. Endocrinology 2002; 143:467-475.
74. Liu F, Qi HL, Chen HL. Effects of all-trans retinoic acid and epidermal growth factor on the expression of nm23-H1 in human hepatocarcinoma cells. J Cancer Res Clin Oncol 2000; 126:85-90.
75. Hartsough MT, Clare SE, Mair M, Elkahloun AG, Sgroi D, Osborne CK, et al. Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res 2001; 61:2320-2327.
76. Yasui W, Oue N, Ono S, Mitani Y, Ito R, Nakayama H. Histone acetylation and gastrointestinal carcinogenesis. Ann N Y Acad Sci 2003; 983:220-231.
77. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003; 22:2034-2044.
78. Ohtsuka T, Zhou T. Bisindolylmaleimide VIII enhances DR5-mediated apoptosis through the MKK4/JNK/p38 kinase and the mitochondrial pathways. J Biol Chem 2002; 277:29294-29303.
79. Steeg PS, de la Rosa A, Flatow U, MacDonald NJ, Benedict M, Leone A. Nm23 and breast cancer metastasis. Breast Cancer Res Treat 1993; 25:175-187.
80. Tagashira H, Hamazaki K, Tanaka N, Gao C, Namba M. Reduced metastatic potential and c-myc overexpression of colon adenocarcinoma cells (Colon 26 line) transfected with nm23-R2/rat nucleoside diphosphate kinase alpha isoform. Int J Mol Med 1998; 2:65-68.
81. Miyazaki H, Fukuda M, Ishijima Y, Takagi Y, Iimura T, Negishi A, et al. Overexpression of nm23-H2/NDP kinase B in a human oral squamous cell carcinoma cell line results in reduced metastasis, differentiated phenotype in the metastatic site, and growth factor-independent proliferative activity in culture. Clin Cancer Res 1999; 5:4301-4307.
82. Yang X, Wei LL, Tang C, Slack R, Mueller S, Lippman ME. Overexpression of KAL1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res 2001; 61:5284-5288.
83. Shevde LA, Samant RS, Goldberg SF, Sikaneta T, Alessandrini A, Donahue HJ, et al. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 2002; 273:229-239.
84. Lee JH, Welch DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 1997; 57:2384-2387.